Patents by Inventor James Stefano
James Stefano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220089763Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: ApplicationFiled: August 17, 2021Publication date: March 24, 2022Inventors: Clark Pan, Qun Zhou, James Stefano, Pradeep Dhal, Bo Chen, Diego Gianolio, Robert Miller, Huawei Qiu
-
Patent number: 11130816Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: GrantFiled: January 3, 2019Date of Patent: September 28, 2021Assignee: GENZYME CORPORATIONInventors: Clark Pan, Qun Zhou, James Stefano, Pradeep Dhal, Bo Chen, Diego Gianolio, Robert Miller, Huawei Qiu
-
Publication number: 20210163584Abstract: Provided are recombinant and chemically-conjugated antibodies and fragments thereof modified with one or more poly-aspartate (poly-D) peptides (e.g., a D10 sequence) to improve localization of the antibodies or fragments to bone. Methods of making and using of these antibodies and fragments also are disclosed.Type: ApplicationFiled: October 23, 2020Publication date: June 3, 2021Applicant: Genzyme CorporationInventors: Huawei Qiu, Sunghae Park, James Stefano
-
Patent number: 10844115Abstract: Provided are recombinant and chemically-conjugated antibodies and fragments thereof modified with one or more poly-aspartate (poly-D) peptides (e.g., a D10 sequence) to improve localization of the antibodies or fragments to bone. Methods of making and using of these antibodies and fragments also are disclosed.Type: GrantFiled: January 19, 2018Date of Patent: November 24, 2020Assignee: Genzyme CorporationInventors: Huawei Qiu, Sunghae Park, James Stefano
-
Patent number: 10806797Abstract: The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon agonist linker conjugate Z-L1-L2-L-Y—R20, wherein Y represents an GLP-1/Glucagon agonist moiety; and -L is a linker moiety—by formula (Ia), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said prodrugs as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon agonist.Type: GrantFiled: June 2, 2016Date of Patent: October 20, 2020Assignee: SANOFIInventors: Dieter Kadereit, Michael Wagner, Thomas Olpp, Nino Meyer, Pradeep Dhal, Paul Konowicz, Robert Miller, James Stefano, Magnus Besev, Martin Bossart, Katrin Lorenz, Torsten Haack, Andreas Evers
-
Patent number: 10792342Abstract: Methods of making ligand-decorated polymer conjugates of therapeutic glycoproteins are described. Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc., which in turn are decorated with target-specific ligands. In some embodiments, acid-labile linkages in such conjugates or rapidly degradable masking groups allow for the intracellular release of the polymer from the glycoprotein, for example, under conditions found in lysosomes.Type: GrantFiled: July 27, 2018Date of Patent: October 6, 2020Assignee: Genzyme CorporationInventor: James Stefano
-
Publication number: 20190233531Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: ApplicationFiled: January 3, 2019Publication date: August 1, 2019Inventors: Clark Pan, Qun Zhou, James Stefano, Pradeep Dhal, Bo Chen, Diego Gianolio, Robert Miller, Huawei Qiu
-
Patent number: 10308917Abstract: The invention provides compositions and methods for treating a disease or disorder associate with vascular endothelial growth factor (VEGF). Specifically, the invention relates to an oligomerized VEGF binding domain to provide VEGF antagonism, and thereby treat diseases associated thereof.Type: GrantFiled: July 25, 2016Date of Patent: June 4, 2019Assignee: GENZYME CORPORATIONInventors: James Stefano, Clark Pan, Huawei Qiu, Michael O'Callaghan, Gloria Matthews
-
Patent number: 10214589Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: GrantFiled: January 27, 2017Date of Patent: February 26, 2019Assignee: GENZYME CORPORATIONInventors: Clark Pan, Qun Zhou, James Stefano, Pradeep Dhal, Bo Chen, Diego Gianolio, Robert Miller, Huawei Qiu
-
Publication number: 20190054154Abstract: Methods of making ligand-decorated polymer conjugates of therapeutic glycoproteins are described. Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc., which in turn are decorated with target-specific ligands. In some embodiments, acid-labile linkages in such conjugates or rapidly degradable masking groups allow for the intracellular release of the polymer from the glycoprotein, for example, under conditions found in lysosomes.Type: ApplicationFiled: July 27, 2018Publication date: February 21, 2019Applicant: Genzyme CorporationInventor: James STEFANO
-
Publication number: 20180289822Abstract: The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon agonist linker conjugate Z-L1-L2-L-Y—R20, wherein Y represents an GLP-1/Glucagon agonist moiety; and -L is a linker moiety—by formula (Ia), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said prodrugs as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon agonist.Type: ApplicationFiled: June 2, 2016Publication date: October 11, 2018Inventors: Dieter KADEREIT, Michael WAGNER, Thomas OLPP, Nino MEYER, Pradeep DHAL, Paul KONOWICZ, Robert MILLER, James STEFANO, Magnus BESEV, Martin BOSSART, Katrin LORENZ, Torsten HAACK, Andreas EVERS
-
Publication number: 20180208650Abstract: Provided are recombinant and chemically-conjugated antibodies and fragments thereof modified with one or more poly-aspartate (poly-D) peptides (e.g., a D10 sequence) to improve localization of the antibodies or fragments to bone. Methods of making and using of these antibodies and fragments also are disclosed.Type: ApplicationFiled: January 19, 2018Publication date: July 26, 2018Applicant: Genzyme CorporationInventors: Huawei Qiu, Sunghae Park, James Stefano
-
Publication number: 20170267774Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: ApplicationFiled: January 27, 2017Publication date: September 21, 2017Inventors: Clark Pan, Qun Zhou, James Stefano, Pradeep Dhal, Bo Chen, Diego Gianolio, Robert Miller, Huawei Qiu
-
Patent number: 9580511Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: GrantFiled: March 10, 2014Date of Patent: February 28, 2017Assignee: GENZYME CORPORATIONInventors: Clark Pan, Qun Zhou, James Stefano, Pradeep Dhal, Bo Chen, Diego Gianolio, Robert Miller, Huawei Qiu
-
Publication number: 20170042979Abstract: Methods of making ligand-decorated polymer conjugates of therapeutic glycoproteins are described. Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc., which in turn are decorated with target-specific ligands. In some embodiments, acid-labile linkages in such conjugates or rapidly degradable masking groups allow for the intracellular release of the polymer from the glycoprotein, for example, under conditions found in lysosomes.Type: ApplicationFiled: October 18, 2016Publication date: February 16, 2017Applicant: Genzyme CorporationInventor: James STEFANO
-
Patent number: 9498518Abstract: Methods of making ligand-decorated polymer conjugates of therapeutic glycoproteins are described. Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc., which in turn are decorated with target-specific ligands. In some embodiments, acid-labile linkages in such conjugates or rapidly degradable masking groups allow for the intracellular release of the polymer from the glycoprotein, for example, under conditions found in lysosomes.Type: GrantFiled: November 6, 2014Date of Patent: November 22, 2016Assignee: GENZYME CORPORATIONInventor: James Stefano
-
Publication number: 20160326501Abstract: The invention provides compositions and methods for treating a disease or disorder associate with vascular endothelial growth factor (VEGF). Specifically, the invention relates to an oligomerized VEGF binding domain to provide VEGF antagonism, and thereby treat diseases associated thereof.Type: ApplicationFiled: July 25, 2016Publication date: November 10, 2016Applicant: Genzyme CorporationInventors: James Stefano, Clark Pan, Huawei Qui, Michael O'Callaghan, Gloria Matthews
-
Patent number: 9441029Abstract: The invention provides compositions and methods for treating a disease or disorder associated with vascular endothelial growth factor (VEGF). Specifically, the invention relates to an oligomerized VEGF binding domain to provide VEGF antagonism, and thereby treat diseases associated thereof.Type: GrantFiled: August 5, 2011Date of Patent: September 13, 2016Assignee: Genzyme CorporationInventors: James Stefano, Clark Pan, Huawei Qiu, Michael O'Callaghan, Gloria Matthews
-
Publication number: 20150320844Abstract: Methods of making ligand-decorated polymer conjugates of therapeutic glycoproteins are described. Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc., which in turn are decorated with target-specific ligands. In some embodiments, acid-labile linkages in such conjugates or rapidly degradable masking groups allow for the intracellular release of the polymer from the glycoprotein, for example, under conditions found in lysosomes.Type: ApplicationFiled: November 6, 2014Publication date: November 12, 2015Applicant: GENZYME CORPORATIONInventor: James Stefano
-
Patent number: 8906379Abstract: Methods of making ligand-decorated polymer conjugates of therapeutic glycoproteins are described. Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc., which in turn are decorated with target-specific ligands. In some embodiments, acid-labile linkages in such conjugates or rapidly degradable masking groups allow for the intracellular release of the polymer from the glycoprotein, for example, under conditions found in lysosomes.Type: GrantFiled: January 20, 2012Date of Patent: December 9, 2014Assignee: Genzyme CorporationInventor: James Stefano